Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Stock Information for Sangamo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sangamo Therapeutics Inc.

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.